• PXR Agonists in Adenine-Induced HFsnEF

  2026-08-27

  This FASEB Journal study introduces a 0.2% adenine-fed mouse model that reproduces key features of heart failure with supranormal ejection fraction, including high ejection fraction, reduced cardiac output, ventricular narrowing, fibrosis, and diastolic dysfunction. The findings associate the phenotype with cardiomyocyte apoptosis and indicate that PXR agonism can mitigate injury through the p53–Bax/Bcl2 pathway, while leaving important questions about intervention identity, dosing, and translation unresolved.

• HEY2, Mitochondrial Respiration, and Cardiac Homeostasis

  2026-08-27

  The reference study identifies HEY2 as an evolutionarily conserved transcriptional brake on cardiac mitochondrial oxidative metabolism. By integrating genetic perturbation, mitochondrial phenotyping, genome-wide analysis, and rescue experiments, it connects HEY2/HDAC1-mediated repression of Ppargc1 and Cpt genes with cardiomyocyte energy failure and heart dysfunction.

• Metabolic Intervention Boosts Ferroptosis and Cuproptosis

  2026-08-26

  This 2024 Chemical Engineering Journal study introduces SCu/L, a copper–tannic acid network/liposome system carrying STF-31 to inhibit glycolysis and compensatory NAD+ metabolism. By lowering NADPH, ATP, and glutathione-related defenses while limiting copper efflux, the strategy enhances ferroptosis and cuproptosis and helps stimulate antitumor immunity.

• ECL Western Blotting Substrate: Workflow Guide

  2026-08-26

  ECL Western Blotting Substrate (SKU K2187) provides a nonradioactive, luminol-based method for detecting HRP-labeled proteins on immunoblots with strong signal and a clear background. It is intended for chemiluminescent Western blot workflows and should not be used as a substitute for fluorescent or radioisotopic detection systems.

• Acetylcholine Chloride for Gut-Brain Assays

  2026-08-25

  Acetylcholine Chloride provides a defined cholinergic comparator for linking microbial signals to colonic, vagal, and neuronal readouts. This practical workflow covers formulation, concentration-response testing, pathway validation, and troubleshooting for gut-brain and neuroscience research.

• IWP-2: Wnt Control in Epithelial Models

  2026-08-25

  IWP-2 is a potent Wnt production inhibitor that reveals how extracellular ligand supply shapes epithelial cell state. This article connects Porcupine inhibition with a 6C corneal culture system, assay interpretation, and carefully bounded cancer research applications.

• EZ Cap EGFP mRNA 5-moUTP: Assay Decision Guide

  2026-08-24

  EZ Cap EGFP mRNA 5-moUTP provides a controlled way to study delivery, translation, stability, and reporter expression. This guide connects its Cap1, 5-moU, and poly(A) design to practical assay choices and to emerging therapeutic mRNA delivery research.

• Cycloastragenol in Glucocorticoid-Induced Osteonecrosis

  2026-08-24

  A 2024 in vivo study found that cycloastragenol reduced femoral-head necrosis, trabecular bone loss, and osteoclast-associated molecular changes in a methylprednisolone-induced rat model of GIONFH. By integrating micro-CT, angiography, histology, qPCR, and Western blotting, the work identifies osteoclast suppression as a measurable hip-preservation strategy while leaving important translational questions unresolved.

• MK-5108 (VX-689): Reliable Cell Assays

  2026-08-23

  This scenario-based guide explains how MK-5108 (VX-689), SKU A4120, can support interpretable Aurora-A perturbation studies in cell viability, proliferation, and cytotoxicity workflows. It covers assay design, DMSO formulation, dose interpretation, and practical criteria for selecting a reliable research reagent.

• PAD4-IN-2 TFA: Tumor-Targeted Workflows

  2026-08-22

  PAD4-IN-2 TFA connects tumor-directed uptake with inhibition of the PAD4–H3cit–NET axis, making it useful for studying cancer-cell migration, neutrophil biology, and immune remodeling in one workflow. This guide translates the Compound 5i TFA evidence base into practical assay design, controls, and troubleshooting decisions.

• Deuterium-Labeled Degarelix: Efficient Synthesis

  2026-08-22

  The reference study reports a 13-step, 14% overall synthesis of deuterium-labeled degarelix acetate, using D2O/D3PO4 to introduce a d7-naphthyl label into an amino-acid precursor. Its main contribution is a practical route to a stable-isotope internal standard for future absorption, distribution, metabolism, and excretion studies of this GnRH receptor antagonist.

• 25-Hydroxycholesterol Rewires TAM Immunometabolism

  2026-08-21

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as a lysosome-centered immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects oxysterol storage, mTORC1 signaling, macrophage suppression, and anti-PD-1 response, providing a framework for testing metabolic interventions in tumor immunity.

• SLC25A1, Senescence, and Cisplatin Resistance in HNSCC

  2026-08-20

  Li et al. identify SLC25A1 as a metabolic and epigenetic regulator of cisplatin resistance in head and neck squamous cell carcinoma, linking mitochondrial citrate transport to H3K27ac-dependent transcription and cellular senescence. The findings position SLC25A1 as a candidate biomarker and therapeutic target while emphasizing the need for multidimensional senescence validation in resistance studies.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-08-20

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines defined immune challenges with pharmacological modulation of cellular metabolism. The workflow preserves blood-based cellular interactions while enabling cytokine responses to be interpreted alongside glycolytic, anabolic, and catabolic perturbations, supporting more reproducible immunometabolism research.

• SFRP1, Wnt/β-Catenin, and Oral Fibrosis

  2026-08-19

  The reference study identifies reduced SFRP1 as a feature of arecoline-induced oral submucous fibrosis and links its loss to neutrophil infiltration, collagen accumulation, and canonical Wnt/β-catenin activation. By combining SFRP1 overexpression with pathway reactivation experiments, the authors provide mechanistic evidence that SFRP1 may limit oral fibrosis through coordinated immune and signaling effects.

8290 records 1/553 page Next 12345 下5页 Last page